Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
- Kumar S.K.
- Lee J.H.
- Lahuerta J.J.
- Morgan G.
- Richardson P.G.
- Crowley J.
- Haessler J.
- Feather J.
- Hoering A.
- Moreau P.
- LeLeu X.
- Hulin C.
- Klein S.K.
- Sonneveld P.
- Siegel D.
- Bladé J.
- Goldschmidt H.
- Jagannath S.
- Miguel J.S.
- Orlowski R.
- Palumbo A.
- Sezer O.
- Rajkumar S.V.
- Durie B.G. International Myeloma Working Group Abildgaard N
- Abonour R
- Alexanian R
- Alsina M
- Anderson KC
- Attal M
- Avet-Loiseau H
- Badros A
- Baris D
- Barlogie B
- Bataille R
- Beksaç M
- Belch A
- Ben-Yehuda D
- Bensinger B
- Bergsagel PL
- Bird J
- Bladé J
- Boccadoro M
- Cavo M
- Chanan-Khan A
- Chen WM
- Child T
- Chim J
- Chng WJ
- Comenzo R
- Crowley J
- Dalton W
- Davies F
- de Souza C
- Delforge M
- Dimopoulos M
- Dispenzieri A
- Drach J
- Drake M
- Durie BG
- Einsele H
- Facon T
- Fantl D
- Fermand JP
- Fonseca R
- Gahrton G
- García-Sanz R
- Gasparetto C
- Gertz M
- Gibson J
- Giralt S
- Goldschmidt H
- Greipp P
- Hajek R
- Hardan I
- Hari P
- Harousseau JL
- Hata H
- Hattori Y
- Heffner T
- Ho J
- Hungria V
- Ida S
- Jacobs P
- Jagannath S
- Johnsen HE
- Jian H
- Joshua D
- Jurczyszyn A
- Kawano M
- Kröger N
- Kumar S
- Kyle RA
- Lacy M
- Lahuerta JJ
- Landgren O
- Laubach J
- Lee JH
- LeLeu X
- Lentzsch S
- Lokhorst H
- Lonial S
- Ludwig H
- Maiolino A
- Mateos M
- Mehta J
- Mellqvist UH
- Merlini G
- Mikhael J
- Morales AR
- Moreau P
- Morgan G
- Nahi H
- Munshi N
- Niesvizky R
- Nouel A
- Novis Y
- Orlowski R
- Palumbo A
- Pavlovsky S
- Pilarski L
- Powles R
- Raje N
- Rajkumar SV
- Reece D
- Reiman T
- Richardson PG
- Roodman D
- Rosiñol L
- San Miguel J
- Sezer O
- Shah JJ
- Shaughnessy J
- Shimizu K
- Shustik C
- Siegel D
- Singhal S
- Sonneveld P
- Spencer A
- Stadtmauer E
- Stewart K
- Terpos E
- Tosi P
- Tricot G
- Turesson I
- Van Camp B
- Van Ness B
- Van Riet I
- Vande Broek I
- Vanderkerken K
- Vescio R
- Vesole D
- Waage A
- Wang M
- Weber D
- Westin J
- Wheatley K
- Zonder J.
DOIAbstract
Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following, refractory to or ineligible to receive, an IMiD (immunomodulatory drug), had measurable disease, and ECOG PS of 0, 1 or 2. The date patients satisfied the entry criteria was defined as time zero (T(0)). The median age at diagnosis was 58 years, and time from diagnosis to T(0) was 3.3 years. Following T(0), 213 (74%) patients had a treatment recorded with one or more regimen...
Add to ORKG